D76.1 Hemophagocytic lymphohistiocytosis

Name of the Condition

• Hemophagocytic lymphohistiocytosis

Summary

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition characterized by excessive immune activation and uncontrolled inflammation. It involves the overproduction of immune cells, particularly histiocytes, which can damage organs such as the liver, spleen, and bone marrow. HLH may occur as a primary (genetic) disorder or secondary to infections, malignancies, or autoimmune diseases. The condition requires prompt recognition and treatment to prevent severe complications.

Causes

HLH can be triggered by genetic mutations (primary HLH) or acquired factors (secondary HLH). Primary HLH results from inherited defects in immune regulation, while secondary HLH is often associated with viral infections (e.g., Epstein-Barr virus), bacterial infections, or underlying malignancies. In some cases, autoimmune disorders or immunosuppressive therapy may also contribute to its development.

Risk Factors

• Genetic predisposition (for primary HLH)
• Severe infections (e.g., viral, bacterial, fungal)
• Malignancies (e.g., lymphoma, leukemia)
• Autoimmune or rheumatologic conditions
• Immunosuppressive therapy or organ transplantation
• Age (more common in infants and young children, but can occur at any age)

Symptoms

Symptoms of HLH are often nonspecific and may include:

• Persistent fever
• Enlarged liver or spleen (hepatosplenomegaly)
• Fatigue or weakness
• Unexplained weight loss
• Bruising or bleeding (due to low platelets)
• Neurological symptoms (e.g., seizures, confusion)
• Skin rashes or jaundice

Diagnosis

Diagnosis of HLH involves a combination of clinical evaluation, laboratory tests, and imaging. Key diagnostic criteria include fever, cytopenias (low blood cell counts), elevated ferritin, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis in bone marrow or spleen, low or absent natural killer (NK) cell activity, and elevated soluble interleukin-2 receptor (sCD25). A biopsy of affected tissue may confirm hemophagocytosis.

Treatment Options

Treatment depends on the underlying cause. For primary HLH, hematopoietic stem cell transplantation may be curative. Secondary HLH focuses on addressing the trigger (e.g., antiviral therapy for infections, chemotherapy for malignancies) and suppressing the overactive immune response with medications like corticosteroids, etoposide, or cyclosporine. Supportive care, including blood transfusions or antibiotics, may also be necessary.

Prognosis and Follow-Up

Prognosis varies based on the underlying cause and timeliness of treatment. Untreated HLH is often fatal, but early intervention can improve outcomes. Long-term follow-up is essential to monitor for recurrence, especially in primary HLH or cases with persistent triggers. Regular blood tests and imaging may be used to assess organ function and immune activity.

Complications

Complications of HLH can include multi-organ failure, severe infections due to immunosuppression, and neurological damage. In severe cases, HLH may progress rapidly, leading to death if not treated promptly. Long-term survivors may experience residual organ dysfunction or require ongoing immunosuppressive therapy.

Lifestyle & Prevention

There is no specific prevention for primary HLH, but managing underlying conditions (e.g., infections, autoimmune diseases) can reduce the risk of secondary HLH. Maintaining good hygiene, avoiding exposure to known triggers, and adhering to prescribed treatments for chronic conditions may help minimize risk. Genetic counseling is recommended for families with a history of primary HLH.

When to Seek Professional Help

Seek immediate medical attention if you experience persistent fever, unexplained fatigue, or signs of organ dysfunction (e.g., jaundice, bruising). Prompt evaluation is critical for diagnosing HLH, as early treatment improves survival. Individuals with a family history of HLH or known genetic predisposition should consult a healthcare provider for monitoring.

Tips for Medical Coders

When coding for hemophagocytic lymphohistiocytosis (D76.1), ensure documentation supports the diagnosis, including clinical findings, laboratory results, and any identified triggers (e.g., infection, malignancy). Differentiate between primary and secondary HLH if specified, as this may impact coding accuracy. Verify that all required diagnostic criteria are documented to justify the code assignment.